Xeroftalmia
Published on April 29, 2026
Risk Factors
Children under 5 in developing countries, severe malnutrition (kwashiorkor/marasmus), fat malabsorption (cystic fibrosis, celiac disease, cholestatic liver disease, chronic pancreatitis), recent measles infection, post-bariatric surgery, chronic alcoholism, exclusive rice-based diets
Etiology
Vitamin A (retinol) deficiency causing impaired epithelial differentiation and reduced rhodopsin synthesis
Presentation
Difficulty seeing at dusk or in dim light (earliest complaint), dry gritty eyes, photophobia, inability to produce tears when crying, frequent respiratory or diarrheal infections
Classic Exam
Bitot's spots (foamy triangular grayish-white patches on bulbar conjunctiva, usually temporal), conjunctival and corneal xerosis, keratomalacia (corneal softening), follicular hyperkeratosis on skin
Diagnostics
Serum retinol (), abnormal dark adaptation test, abnormal electroretinography, low retinol-binding protein
Management
High-dose oral vitamin A on day 1, day 2, and day 15 (dosing by age); treat underlying cause; manage corneal complications urgently
Keywords
"Cannot see at dusk," "night blindness," "Bitot's spots," "foamy white triangular patches," "malnourished child after measles," "rice-only diet," "cystic fibrosis with dry eyes"
01Pathophysiology
Vitamin A (retinol) is a fat-soluble vitamin with two roles in ocular health: maintaining epithelial integrity through mucin-producing goblet cells and serving as the substrate for rhodopsin synthesis in rod photoreceptors. When you understand these two roles, the entire clinical picture writes itself.
In the retina, retinol is converted to 11-cis-retinal, which combines with opsin to form rhodopsin, the visual pigment responsible for vision in low-light conditions. When vitamin A drops, rhodopsin cannot be regenerated quickly enough after light exposure, and the rods fail first. This is why nyctalopia (night blindness) is always the earliest symptom; cones, which handle daytime and color vision, are spared until very late.
In the conjunctiva and cornea, vitamin A drives the differentiation of mucin-secreting goblet cells. Without it, these cells disappear and the surface epithelium undergoes squamous metaplasia with keratinization. The conjunctiva loses its glistening moist appearance and becomes dry and wrinkled (xerosis). Keratin debris and saprophytic bacteria (often Corynebacterium xerosis) accumulate over devitalized epithelium, producing the pathognomonic Bitot's spots.
If deficiency continues, the cornea itself dries, the stroma liquefies, and the eye undergoes keratomalacia, a rapid colliquative necrosis that can perforate the globe within 24 to 48 hours. This is why advanced xerophthalmia is a true ophthalmic emergency. The same epithelial dysfunction explains the increased susceptibility to measles, diarrhea, and respiratory infections, since vitamin A maintains mucosal barriers everywhere, not just in the eye.
A clinically important detail: measles depletes vitamin A stores acutely by reducing serum retinol and increasing urinary loss. A previously borderline child can crash into florid xerophthalmia within days of a measles episode. This bidirectional relationship (deficiency worsens measles, measles worsens deficiency) is heavily tested.
02Clinical Manifestation and Classification (WHO Staging)
XN
Stage
Night blindness
Clinical Finding
Difficulty seeing in dim light; child bumps into objects at dusk
Reversibility
Fully reversible
X1A
Stage
Conjunctival xerosis
Clinical Finding
Dry, dull, wrinkled bulbar conjunctiva
Reversibility
Fully reversible
X1B
Stage
Bitot's spots
Clinical Finding
Foamy triangular grayish-white plaques (Bitot's spots) on temporal bulbar conjunctiva
Reversibility
Reversible
X2
Stage
Corneal xerosis
Clinical Finding
Hazy, dry cornea with punctate keratopathy
Reversibility
Reversible with prompt treatment
X3A
Stage
Corneal ulceration / keratomalacia, less than one-third of cornea
Clinical Finding
Sharply demarcated ulcer or area of softening
Reversibility
Partial scarring expected
X3B
Stage
Corneal ulceration / keratomalacia, one-third or more of cornea
Clinical Finding
Extensive corneal melting, risk of perforation
Reversibility
Vision loss likely
XS
Stage
Corneal scar
Clinical Finding
Healed opacity from prior keratomalacia
Reversibility
Permanent
XF
Stage
Xerophthalmic fundus
Clinical Finding
Whitish peripheral retinal lesions
Reversibility
Reversible
Code | Stage | Clinical Finding | Reversibility |
|---|---|---|---|
XN | Night blindness | Difficulty seeing in dim light; child bumps into objects at dusk | Fully reversible |
X1A | Conjunctival xerosis | Dry, dull, wrinkled bulbar conjunctiva | Fully reversible |
X1B | Bitot's spots | Foamy triangular grayish-white plaques (Bitot's spots) on temporal bulbar conjunctiva | Reversible |
X2 | Corneal xerosis | Hazy, dry cornea with punctate keratopathy | Reversible with prompt treatment |
X3A | Corneal ulceration / keratomalacia, less than one-third of cornea | Sharply demarcated ulcer or area of softening | Partial scarring expected |
X3B | Corneal ulceration / keratomalacia, one-third or more of cornea | Extensive corneal melting, risk of perforation | Vision loss likely |
XS | Corneal scar | Healed opacity from prior keratomalacia | Permanent |
XF | Xerophthalmic fundus | Whitish peripheral retinal lesions | Reversible |
The progression follows a predictable sequence: rod dysfunction first (XN), then conjunctiva (X1), then cornea (X2 to X3), and finally scarring (XS). On a vignette, the stage tells you the urgency. XN through X1B are outpatient problems; X2 onwards is an emergency.
03Diagnostic Workup
Serum retinol
Purpose
Confirms biochemical deficiency
Threshold / Finding
(deficient); (severe)
Dark adaptation test
Purpose
Functional rod assessment
Threshold / Finding
Delayed adaptation curve
Electroretinography
Purpose
Detects subclinical rod dysfunction
Threshold / Finding
Reduced scotopic b-wave amplitude
Conjunctival impression cytology
Purpose
Documents goblet cell loss
Threshold / Finding
Absence of goblet cells, presence of keratinized epithelium
Retinol-binding protein
Purpose
Surrogate marker (cheaper)
Threshold / Finding
Reduced
Therapeutic trial
Purpose
Confirms diagnosis when labs unavailable
Threshold / Finding
Resolution of night blindness within 48 hours of vitamin A dosing
Test | Purpose | Threshold / Finding |
|---|---|---|
Serum retinol | Confirms biochemical deficiency | (deficient); (severe) |
Dark adaptation test | Functional rod assessment | Delayed adaptation curve |
Electroretinography | Detects subclinical rod dysfunction | Reduced scotopic b-wave amplitude |
Conjunctival impression cytology | Documents goblet cell loss | Absence of goblet cells, presence of keratinized epithelium |
Retinol-binding protein | Surrogate marker (cheaper) | Reduced |
Therapeutic trial | Confirms diagnosis when labs unavailable | Resolution of night blindness within 48 hours of vitamin A dosing |
In practice, xerophthalmia is a clinical diagnosis. A malnourished preschool child with night blindness and Bitot's spots needs vitamin A immediately. You do not wait for serum retinol to come back. Laboratory confirmation is for atypical presentations, malabsorption workups, or research settings.
For research-level confirmation, conjunctival impression cytology (showing loss of goblet cells and keratinized epithelium) is the histologic gold standard, and electroretinography is the functional gold standard for subclinical rod dysfunction. These rarely show up as test answers but worth recognizing.
A common vignette twist is the child with cystic fibrosis or biliary atresia presenting with night blondness or dry eyes. Here, the deficiency is from fat malabsorption, not poor intake, and the workup adds fecal elastase, sweat chloride, or cholestasis evaluation.
04Management and Treatment
Infants under 6 months
Day 1 Dose
50,000 IU orally
Day 2 Dose
50,000 IU orally
Day 15 Dose
50,000 IU orally
Infants 6 to 12 months
Day 1 Dose
100,000 IU orally
Day 2 Dose
100,000 IU orally
Day 15 Dose
100,000 IU orally
Children over 12 months and adults
Day 1 Dose
200,000 IU orally
Day 2 Dose
200,000 IU orally
Day 15 Dose
200,000 IU orally
Population | Day 1 Dose | Day 2 Dose | Day 15 Dose |
|---|---|---|---|
Infants under 6 months | 50,000 IU orally | 50,000 IU orally | 50,000 IU orally |
Infants 6 to 12 months | 100,000 IU orally | 100,000 IU orally | 100,000 IU orally |
Children over 12 months and adults | 200,000 IU orally | 200,000 IU orally | 200,000 IU orally |
The acute treatment of xerophthalmia rests on a three-dose oral regimen: a dose on day 1, repeated on day 2, and a third dose on day 15. The day 15 dose replenishes hepatic stores. Oil-based oral preparations are preferred. Intramuscular water-miscible vitamin A is reserved for children with severe vomiting, severe diarrhea, or malabsorption who cannot retain the oral dose.
Alongside vitamin A, manage the underlying cause. In protein-energy malnutrition, refeeding must accompany supplementation since retinol-binding protein synthesis requires adequate protein. In cystic fibrosis or cholestatic liver disease, give pancreatic enzyme replacement and use water-miscible vitamin A formulations that do not require bile salts for absorption. In recent measles, the WHO recommends two doses of vitamin A on consecutive days regardless of nutritional status because measles precipitates acute deficiency.
Corneal complications are an emergency. Keratomalacia (X3A or X3B) requires immediate vitamin A, topical antibiotics to prevent superinfection, atropine for cycloplegia, and a protective eye shield. Avoid topical steroids; they accelerate corneal melting. Patching is contraindicated in active ulceration. Ophthalmology consultation should not be delayed.
Pregnancy is the major contraindication trap. High-dose vitamin A (above 10,000 IU per day in early pregnancy) is teratogenic, causing craniofacial, cardiac, thymic, and central nervous system malformations. For pregnant or potentially pregnant women with mild xerophthalmia (night blindness or Bitot's spots only), use the low-dose regimen of 5,000 to 10,000 IU daily or 25,000 IU weekly. However, when corneal disease threatens vision, the full sight-saving dose is given because blindness in the mother outweighs theoretical fetal risk.
The next best step logic to memorize:
Night blindness in a malnourished child, no eye findings yet: oral vitamin A immediately, do not wait for labs.
Bitot's spots present: oral vitamin A immediately plus dietary counseling.
Corneal involvement: oral vitamin A plus topical antibiotic plus eye shield plus urgent ophthalmology referral.
Recent measles in a child from an endemic area: prophylactic vitamin A on two consecutive days regardless of eye findings.
Pregnant patient with night blindness: low-dose daily or weekly regimen, never the high-dose pulse.
05Prophylaxis and Public Health Prevention
Infants 6 to 11 months
Capsule Color
Blue (kapsul biru)
Dose
100,000 IU
Schedule
February or August
Frequency
Once per year
Children 12 to 59 months
Capsule Color
Red (kapsul merah)
Dose
200,000 IU
Schedule
February and August
Frequency
Twice per year
Postpartum mothers (ibu nifas, 0 to 42 days)
Capsule Color
Red (kapsul merah)
Dose
200,000 IU
Schedule
Dose 1: immediately after delivery
Dose 2: 24 hours after the first dose
Frequency
Two doses total per delivery
Target Group | Capsule Color | Dose | Schedule | Frequency |
|---|---|---|---|---|
Infants 6 to 11 months | Blue (kapsul biru) | 100,000 IU | February or August | Once per year |
Children 12 to 59 months | Red (kapsul merah) | 200,000 IU | February and August | Twice per year |
Postpartum mothers (ibu nifas, 0 to 42 days) | Red (kapsul merah) | 200,000 IU |
| Two doses total per delivery |
Indonesia runs one of the longest-standing universal vitamin A supplementation programs in the world. The program operates through Posyandu, Puskesmas, Pustu, Poskesdes, and partner facilities, and the capsules are distributed free of charge.
The two designated months are February (Februari) and August (Agustus), chosen so that supplementation occurs roughly every six months and aligns with hepatic storage capacity. Vitamin A is fat-soluble and stored in the liver, so a single high-dose pulse can cover the body's needs for approximately four to six months without requiring daily dosing.
Two capsule preparations are used:
The blue capsule (kapsul biru) contains 100,000 IU of retinol palmitate or acetate and is given to infants aged 6 to 11 months. Infants in this age band receive the capsule once a year, either in February or in August, depending on when they cross the six-month threshold. Vitamin A supplementation is not started before six months of age because exclusive breastfeeding is the recommended source until then, and breast milk from a well-nourished mother provides adequate vitamin A.
The red capsule (kapsul merah) contains 200,000 IU and is given to children aged 12 to 59 months twice a year, once in February and once in August. The same red capsule is used for postpartum mothers.
The administration technique is straightforward: snip the nipple of the soft capsule with clean scissors, squeeze the contents directly into the child's mouth, and ensure the entire dose is swallowed.
Postpartum mothers up to 42 days after delivery receive two doses of the red 200,000 IU capsule. The first dose is given immediately after delivery, and the second dose is given at least 24 hours after the first dose. The rationale rests on breast milk pharmacology: a single 200,000 IU dose raises breast milk vitamin A content for approximately 60 days, while the two-dose regimen extends adequate breast milk vitamin A content through the first six months of the infant's life, covering the period of exclusive breastfeeding. This is the strategy by which Indonesia protects infants under six months from deficiency without giving the infant any direct supplementation.
If a mother misses the immediate postpartum dose, she can still receive the capsule any time within the 42-day puerperium window. After day 42, she is no longer eligible.
06Differential Diagnosis and Distractors
Sjögren syndrome
Why It Is Similar
Both present with dry eyes and gritty sensation
Key Discriminator
Sjögren occurs in middle-aged women with dry mouth, positive anti-Ro/anti-La antibodies, and no night blindness; xerophthalmia features nyctalopia and Bitot's spots
Retinitis pigmentosa
Why It Is Similar
Both cause night blindness
Key Discriminator
Retinitis pigmentosa shows bone-spicule pigmentation on fundoscopy, peripheral visual field constriction, and family history; vitamin A levels are normal
Allergic conjunctivitis with xerosis
Why It Is Similar
Both can show conjunctival changes
Key Discriminator
Allergic disease has itching, papillae, and seasonal pattern; no Bitot's spots, no night blindness
Stevens-Johnson syndrome sequelae
Why It Is Similar
Causes severe ocular surface dryness and goblet cell loss
Key Discriminator
History of drug reaction with mucocutaneous involvement; symblepharon present
Trachoma
Why It Is Similar
Endemic in similar populations, causes corneal scarring
Key Discriminator
Trachoma shows tarsal follicles, Herbert's pits, and trichiasis; caused by Chlamydia trachomatis, not nutritional
Vitamin B2 (riboflavin) deficiency
Why It Is Similar
Can cause photophobia and corneal vascularization
Key Discriminator
Riboflavin deficiency features angular cheilitis, glossitis, and seborrheic dermatitis; no night blindness or Bitot's spots
Congenital stationary night blindness
Why It Is Similar
Lifelong night blindness
Key Discriminator
Present from birth, no nutritional history, normal serum retinol, often X-linked
Measles keratoconjunctivitis (without deficiency)
Why It Is Similar
Both can occur in the same child
Key Discriminator
Pure measles eye disease resolves with the rash; persistent corneal changes after the acute illness signal underlying vitamin A deficiency
Differential Diagnosis | Why It Is Similar | Key Discriminator |
|---|---|---|
Sjögren syndrome | Both present with dry eyes and gritty sensation | Sjögren occurs in middle-aged women with dry mouth, positive anti-Ro/anti-La antibodies, and no night blindness; xerophthalmia features nyctalopia and Bitot's spots |
Retinitis pigmentosa | Both cause night blindness | Retinitis pigmentosa shows bone-spicule pigmentation on fundoscopy, peripheral visual field constriction, and family history; vitamin A levels are normal |
Allergic conjunctivitis with xerosis | Both can show conjunctival changes | Allergic disease has itching, papillae, and seasonal pattern; no Bitot's spots, no night blindness |
Stevens-Johnson syndrome sequelae | Causes severe ocular surface dryness and goblet cell loss | History of drug reaction with mucocutaneous involvement; symblepharon present |
Trachoma | Endemic in similar populations, causes corneal scarring | Trachoma shows tarsal follicles, Herbert's pits, and trichiasis; caused by Chlamydia trachomatis, not nutritional |
Vitamin B2 (riboflavin) deficiency | Can cause photophobia and corneal vascularization | Riboflavin deficiency features angular cheilitis, glossitis, and seborrheic dermatitis; no night blindness or Bitot's spots |
Congenital stationary night blindness | Lifelong night blindness | Present from birth, no nutritional history, normal serum retinol, often X-linked |
Measles keratoconjunctivitis (without deficiency) | Both can occur in the same child | Pure measles eye disease resolves with the rash; persistent corneal changes after the acute illness signal underlying vitamin A deficiency |
The two highest-yield distractors are retinitis pigmentosa (chosen when the test-taker latches onto night blindness in isolation) and Sjögren syndrome (chosen when the test-taker latches onto dry eyes). The discriminators are nutritional context, age group, and the presence of Bitot's spots.
07Traps and High-Yield Pearls
The single most common error on questions about xerophthalmia is stopping at the first symptom and missing the staging. A child with night blindness alone has reversible disease and needs vitamin A; a child with corneal melting needs vitamin A plus topical antibiotics plus an eye shield plus emergency referral. The vignette will almost always describe physical findings precisely so that you can place the patient on the WHO staging ladder, and the right management answer depends on which rung the patient is on.
The second classic trap is the pregnant patient. Test writers love to set up a malnourished pregnant woman with night blindness and offer a 200,000 IU pulse dose as a tempting answer. This is wrong because of teratogenicity. The correct approach in mild disease during pregnancy is daily low-dose supplementation (5,000 to 10,000 IU per day) or weekly dosing (25,000 IU per week). The 200,000 IU pulse is reserved for sight-threatening corneal disease where the maternal benefit outweighs fetal risk.
The third trap is the post-measles child. A vignette describing a preschool child from a low-resource setting who developed eye complaints "two weeks after recovering from a febrile rash" is testing whether you recognize that measles unmasks subclinical vitamin A deficiency. The answer is vitamin A on two consecutive days, even before any laboratory confirmation.
The fourth trap is the fat malabsorption presentation. A teenager with cystic fibrosis or a child with biliary atresia presenting with dry eyes and night blindness is testing whether you understand that vitamin A is fat-soluble. Oral oil-based preparations will not work; you need water-miscible vitamin A and treatment of the underlying malabsorption. Other fat-soluble vitamin deficiencies (D, E, K) often coexist and may be tested in the same vignette.
The fifth and most subtle trap is mistaking Bitot's spots for pinguecula or pterygium. Pinguecula and pterygium are degenerative changes in adults from sun exposure; Bitot's spots are foamy keratinized patches in malnourished children. The age and nutritional context decide.
The core competency being tested is recognition of a clinical syndrome that combines a nutritional history, a pathognomonic eye finding, and a staged emergency response. Test writers reward candidates who can move quickly from "malnourished child with night blindness" to "give oral vitamin A now" without waiting for serum retinol, and who can adjust the dose for pregnancy and the route for malabsorption. Master the staging table, the dosing schedule, and the pregnancy exception, and questions on this topic become free points.